This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated POT1 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-POT1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~71.4 kDa | |
| Observed band | ~71 kDa | |
| Gel | 10–12% | |
| Negative control | siRNA / KO lysate |
| PTM | — | |
| Caveat | Alternative splicing isoforms | |
| Regulation | IFN-γ-induced | |
| Isoform | 2 isoform(s) |
Literature-validated Western blot parameters for POT1 — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | human Hela , Lane 2: human K562 , Lane 3: rat brain , Lane 4: rat liver , Lane 5: mouse Neuro-2a . After Electrophoresis, proteins were transferred to a Nitrocellulose membrane at 150mA for 50-90 minutes. Blocked the membrane with 5% Non-fat Milk/ TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-POT1 antigen affinity purified polyclonal antibody (Catalog # PB9780) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:10000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for POT1 at approximately 71KD. The expected band size for POT1 is at 71KD |
| Gel % | 10–12% |
| Load | 50ug |
| Transfer | nitrocellulose membrane, 150 mA, 50–90 min |
| Membrane | nitrocellulose |
| Blocking | 5% non-fat milk / TBS, 1.5 h RT |
| Primary antibody | 0.5 µg/mL |
| Primary incubation | overnight at 4 °C |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:10000 |
| Wash | TBS-0.1% Tween, 3 × 5 min |
| Detection | ECL |
| Exposure / imaging | Tanon 5200 |
| Observed band | 71 kDa |
POT1 has a 71.4 kDa predicted mass and runs at the same ~71 kDa observed band, consistent with an unmodified monomer despite its native, non-covalent homodimer/shelterin partnering.
| Single band at ~71 kDa | Matches the predicted full-length POT1 mass; no glycosylation or proteolytic cleavage to shift the apparent size |
| Band present in nuclear/chromatin-enriched lysate but faint in cytoplasmic-only prep | POT1 is a nuclear, telomere-chromatin-associated protein rather than a secreted one, so it concentrates in nuclear/whole-cell lysates |
| Faint second band at a different apparent mass | Two annotated splice isoforms (isoform 1 and isoform 2) exist, so a minor secondary species distinct from the canonical band is possible |
| No shift in band position after non-reducing versus reducing sample prep | POT1 homodimerizes/oligomerizes through protein-protein contacts within the shelterin complex, not inter-chain disulfide bonds, so SDS denaturation dissociates it back to monomer regardless of reducing agent |
| No mass shift after PNGase F or deglycosylation treatment | POT1 has no annotated N- or O-glycosylation sites, so enzymatic deglycosylation is not expected to change its migration |
| Predicted mass (71.4 kDa, 634 aa) | Sets the baseline monomer band size, consistent with the observed ~71 kDa band |
| Absence of glycosylation sites | No smearing or upward mass shift from glycan attachment; band should run sharp at the predicted size |
| No signal peptide or propeptide | No precursor-to-mature cleavage step, so no smaller processed fragment is expected, only the full-length band |
| Homodimer/homooligomer formation (non-covalent, no disulfide bonds) | Standard reducing, SDS-denaturing conditions dissociate the oligomer to monomer; a higher apparent-mass species appears only if the complex is incompletely denatured or run natively |
| Two annotated splice isoforms (isoform 1, isoform 2) | Isoform 2 may contribute an additional band at a different apparent mass than the canonical isoform, though no isoform-specific size is defined |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | Incomplete denaturation preserves POT1's homodimer/homooligomer or shelterin-complex interactions | Boil samples longer in fresh SDS/reducing sample buffer and avoid native run conditions |
| Multiple bands | Two annotated splice isoforms or partial degradation of this large nuclear protein | Confirm target identity against the antibody's immunogen region and include fresh protease inhibitors during lysis |
| Weak or no signal | POT1 is a lower-abundance, telomere-chromatin-associated nuclear protein | Enrich the nuclear/chromatin fraction, load more total protein, and use a sensitive ECL substrate |
| No band in lysate | Standard cytoplasmic-only lysis may not efficiently solubilize chromatin-bound nuclear POT1 | Use a nuclear extraction protocol with sonication or benzonase rather than a cytoplasmic-only buffer |
| Broad smear instead of sharp band | With no glycosylation sites annotated, a smear more likely reflects degradation or aggregation than glycoform heterogeneity | Keep samples cold, add fresh protease inhibitors, and avoid repeated freeze-thaw cycles |
| Fragments below expected size | Proteolytic degradation of this large nuclear protein during extraction | Minimize processing time and use a fresh protease inhibitor cocktail during lysis |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for POT1, answered from its protein features.
BosterBio's POT1 antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
The anti-POT1 antibodies below represent our top-performing, most cited Western blot reagents, rigorously validated through orthogonal approaches including negative-tissue controls and complementary detection methods. Each has been thoroughly characterized to ensure specific, reproducible detection of POT1 across sample types.
Which to pick: Only one Boster POT1 antibody is catalogued, PB9780, which includes an actual Western blot validation image showing the expected band—making it the clear default choice for POT1 detection until additional clones are validated.